Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Kabra Drugs

524322
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Kabra Drugs Share price and Fundamental Analysis

View All Details
View All Details
Kabra Drugs Ltd was incorporated on August 22, 1989 as a Private Limited Company. Subsequently, the company was converted into a Public Limited Company on April 1, 1992. The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solvent Ether, Ethyl Chloride Spray (General Anesthesia) and Surgical. The commercial production commenced in 1991. Kabra Drugs Limited is the only manufacturer of Ether derivatives in the State of M.P.
Company Incorporation1989
ChairmanNA
Head QuartersNA
Previous NameKabra Drugs Ltd

Key Metrics

Market Cap (Cr)
28.95
PE Ratio
0
Industry P/E
35.21
PEG Ratio
0
ROE
-4.4%
ROCE
-4.32%
ROA
-4.36%
Total Debt (Cr)
0.44
Debt to Equity
0.02
Dividend Yield
0%
EPS
0
Book Value & P/B
10.4 x 1.17
Face Value
10
Outstanding Shares(Cr)
2.37
Current Ratio
184.47
EV to Sales
0

Stock Returns

1 Week+4.99%
1 Month+4.99%
6 Months+21.37%
1 Year+54.36%
3 Years+163.71%
5 Years+221.32%

CAGR

1 Year CAGR

Revenue Growth

N/A

Net Profit Growth

+117.84%

Operating Profit Growth

+117.84%

Dividend Growth

N/A

Stock Returns CAGR

+54.36%
no_data

No Stocks

Smart Score

1.8
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Mar 25

Promoters : 0.00%

FIIs : 0.00%

DIIs : 0.00%

Public : 100.00%

Promoter
FII/FPI
DII
Public

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Kabra Drugs Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Kabra Drugs Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Kabra Drugs Ltd was incorporated on August 22, 1989 as a Private Limited Company. Subsequently, the company was converted into a Public Limited Company on April 1, 1992. The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solvent Ether, Ethyl Chloride Spray (General Anesthesia) and Surgical. The commercial production commenced in 1991. Kabra Drugs Limited is the only manufacturer of Ether derivatives in the State of M.P.

The latest addition to the product line is the range of disinfectants which includes hand wash gel, hand sanitizer and antimicrobial gel. In India there are very few manufacturers who are manufacturing the said products. The company is the sole manufacturer of antimicrobial hand wash gel and other disinfectant products in India. The company is also a registered supplier to the Ministry of Defence.

With manufacturing and regular supply in the domestic market for injectables, soft gelatin capsules and liquids (oral and external especially alcohol products) the company now looks at the global market. A number of new products have been developed for the same.

Kabra Drugs Share Price

Kabra Drugs share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Kabra Drugs Market Cap

Market capitalization of Kabra Drugs indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Kabra Drugs is valued compared to its competitors.

Kabra Drugs PE Ratio

Kabra Drugs PE ratio helps investors understand what is the market value of each stock compared to Kabra Drugs 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Kabra Drugs PEG Ratio

The PEG ratio of Kabra Drugs evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Kabra Drugs ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Kabra Drugs generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Kabra Drugs ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Kabra Drugs in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Kabra Drugs Total Debt

Total debt of Kabra Drugs shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Kabra Drugs Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Kabra Drugs compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Kabra Drugs CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Kabra Drugs over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Kabra Drugs Technical Analysis

Technical analysis of Kabra Drugs helps investors get an insight into when they can enter or exit the stock. Key components of Kabra Drugs Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Kabra Drugs shares often struggle to rise above due to selling pressure.

Kabra Drugs Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Kabra Drugs ’s financial health and profitability.

Kabra Drugs Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Kabra Drugs Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Kabra Drugs Financials

The financials of Kabra Drugs provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Kabra Drugs Profit and Loss Statements

The profit and loss statement of Kabra Drugs highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Kabra Drugs .

Kabra Drugs Balance Sheet

The balance sheet presents a snapshot of Kabra Drugs ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Kabra Drugs Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App